AstraZeneca, one of the leading bio-tech companies, is receiving various interest reviews from market experts. The company is being eyed as one of the best
vaccine,
weight loss drug, and
immunotherapy stocks worth purchasing, according to Hedge Funds and analysts.
New York State Common Retirement Fund,
Oxbow Advisors LLC, and
NewEdge Wealth LLC have reportedly increased their stakes in the company, reflecting positive investor sentiment. However, concerns surrounding its China operations have led to fluctuations in stock prices, with shares initially dipping before recovering after reassuring updates on the probe. An ongoing lawsuit and possible probe fallout are causing investor nervousness. In terms of financial performance, Goldman Sachs has lowered AstraZeneca's stock price target while FTSE 100 reported a significant surge, and Q4 earnings beat expectations despite sales drops in China. Various investors, analysts, and hedge funds are betting on the company's growth potential, promoting it as one of the best international dividend and cheap growth stocks, drawing significant attention with its focus on the U.S.
AstraZeneca Stocks News Analytics from Tue, 10 Sep 2024 07:00:00 GMT to Sat, 01 Mar 2025 19:55:25 GMT -
Rating 3
- Innovation 4
- Information 8
- Rumor -2
